The exact cause of such effects is not known, although aggressive research in this area is underway. Irrespective of the cause, a patient with full-blown Parkinson’s disease will have four cardinal symptoms, tremor at rest, bradykinesia, rigidity, and difficulties with balance. Such patients due to difficulty in movement control are virtually rendered nonfunctional, and the quality of their life is severely affected (1).
From the market point of view, thus there is huge untapped potential in the Parkinsons disease therapy market. The exact cause of the disease is not known, but a considerable number of individuals suffer from this problem. The medical therapy assumes a central role in the management plan, and therefore a variety of medications are available for symptomatic treatment. Despite new research to discover newer drugs, there is no medication as yet which has shown promise in arresting the pathological process of the Parkinsons disease. Therefore, this existing gap can create opportunities newer modalities of therapies, therapeutic agents, or curative agents (1).
The Worldwide market of Parkinson’s disease is huge, since it is a common neurological disease with a disease burden of 4.1m affected individual. It is expected that its prevalence will rise in the coming years with increased clinical interventions in different forms. Current treatments or therapeutic choices are unsatisfactory making the unmet needs of this market a huge one, creating significant market opportunity. Although the market is global, in developed world, almost all counties constitute the major markets of such drugs. These countries are USA, Japan, France, Italy, Germany, Spain, and the UK. Compared to last evaluation of 2006 the market has been predicted to grow beyond $4.6bn from its base of $2.2bn, which interestingly was 11% larger than its base of 2005. The market is expected to increase in an exponential rate due to the fact that